JP2023520462A5 - - Google Patents
Info
- Publication number
- JP2023520462A5 JP2023520462A5 JP2022559922A JP2022559922A JP2023520462A5 JP 2023520462 A5 JP2023520462 A5 JP 2023520462A5 JP 2022559922 A JP2022559922 A JP 2022559922A JP 2022559922 A JP2022559922 A JP 2022559922A JP 2023520462 A5 JP2023520462 A5 JP 2023520462A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- independently
- alkyl
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004639P | 2020-04-03 | 2020-04-03 | |
| US63/004,639 | 2020-04-03 | ||
| PCT/US2021/025558 WO2021202986A1 (en) | 2020-04-03 | 2021-04-02 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520462A JP2023520462A (ja) | 2023-05-17 |
| JP2023520462A5 true JP2023520462A5 (cg-RX-API-DMAC10.html) | 2024-04-10 |
Family
ID=75728888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559922A Pending JP2023520462A (ja) | 2020-04-03 | 2021-04-02 | フリードライヒ運動失調症を含むミトコンドリア病の予防および／または治療のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037350B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4126836A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023520462A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230005855A (cg-RX-API-DMAC10.html) |
| CN (4) | CN115996916B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021246142A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3176909A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL296985A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021202986A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022291142A1 (en) | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024263742A1 (en) * | 2023-06-22 | 2024-12-26 | Stealth Biotherapeutics Inc. | Combination therapy for the treatment of friedreich's ataxia |
| AU2024300048A1 (en) * | 2023-07-21 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| AU2024377199A1 (en) | 2023-11-09 | 2026-05-21 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP2332534B1 (en) | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (cg-RX-API-DMAC10.html) | 2009-08-26 | 2018-06-30 | ||
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| EP2606022A2 (en) | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| EP3377179B1 (en) | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| IL305687B2 (en) | 2017-12-15 | 2024-12-01 | Stealth Biotherapeutics Inc | Mitochondria-targeting peptides |
-
2021
- 2021-04-02 CA CA3176909A patent/CA3176909A1/en active Pending
- 2021-04-02 CN CN202180040296.8A patent/CN115996916B/zh active Active
- 2021-04-02 EP EP21722328.8A patent/EP4126836A1/en active Pending
- 2021-04-02 IL IL296985A patent/IL296985A/en unknown
- 2021-04-02 CN CN202510664780.8A patent/CN120554211A/zh active Pending
- 2021-04-02 JP JP2022559922A patent/JP2023520462A/ja active Pending
- 2021-04-02 CN CN202511246796.3A patent/CN121085765A/zh active Pending
- 2021-04-02 WO PCT/US2021/025558 patent/WO2021202986A1/en not_active Ceased
- 2021-04-02 US US17/221,463 patent/US12037350B2/en active Active
- 2021-04-02 CN CN202511246906.6A patent/CN121085756A/zh active Pending
- 2021-04-02 KR KR1020227038265A patent/KR20230005855A/ko active Pending
- 2021-04-02 AU AU2021246142A patent/AU2021246142A1/en active Pending
-
2024
- 2024-05-23 US US18/672,819 patent/US20240400588A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100567275C (zh) | 作为免疫抑制剂的5-(苯基-(z)-亚基)-噻唑烷-4-酮衍生物 | |
| ES2629927T3 (es) | Compuesto para el tratamiento del cáncer | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU97119064A (ru) | Применение альфа(il)-агонистов для лечения недержания мочи | |
| JP2006501181A5 (cg-RX-API-DMAC10.html) | ||
| CA2168751A1 (en) | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus | |
| JP2003513090A (ja) | Ｎ置換カルバモイルオキシアルキルアゾリウム誘導体 | |
| KR880005092A (ko) | 항궤양제로서 유효한 벤즈이미다졸의 신규 유도체 | |
| JP2006507326A5 (cg-RX-API-DMAC10.html) | ||
| GB2044754A (en) | Imidazoles | |
| MY117290A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | |
| JP2021535213A5 (cg-RX-API-DMAC10.html) | ||
| RU2007108863A (ru) | Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3 | |
| JPH05502872A (ja) | 医薬 | |
| JP2020516616A5 (cg-RX-API-DMAC10.html) | ||
| JP2021513543A5 (cg-RX-API-DMAC10.html) | ||
| KR930004262A (ko) | 메타노안트라센 화합물 | |
| JP2024527604A5 (cg-RX-API-DMAC10.html) | ||
| CA2373395A1 (en) | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | |
| KR20230169982A (ko) | 리보솜 장애와 관련된 빈혈을 치료하기 위한 조성물 및 방법 | |
| GB2038800A (en) | Antihypertensive sulphurcontaining compounds | |
| JP2024037892A5 (cg-RX-API-DMAC10.html) | ||
| WO1993005026A1 (en) | Peptide isoters containing a heterocycle as h.i.v. inhibitors | |
| RU2007140788A (ru) | Монолизиновые соли производных азола | |
| JP2005029573A (ja) | 腫瘍転移抑制剤 |